

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infection

Favresse, Julien; Cabo, Julien; Douxfils, Jonathan

Published in:
Journal of Infection

DOI:
[10.1016/j.jinf.2023.05.014](https://doi.org/10.1016/j.jinf.2023.05.014)

Publication date:
2023

Document Version
Version created as part of publication process; publisher's layout; not normally made publicly available

[Link to publication](#)

Citation for pulished version (HARVARD):
Favresse, J, Cabo, J & Douxfils, J 2023, 'Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infection', *Journal of Infection*, vol. 87, no. 2, pp. e31-e32.
<https://doi.org/10.1016/j.jinf.2023.05.014>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infectionRunning title: Cellular immunity and the serological status

Julien Favresse
Julien Cabo
Jonathan Douxfls



PII: S0163-4453(23)00292-X
DOI: <https://doi.org/10.1016/j.jinf.2023.05.014>
Reference: YJINF5969

To appear in: *Journal of Infection*
Accepted date: 16

Please cite this article as: Julien Favresse, Julien Cabo and Jonathan Douxfls, Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infectionRunning title: Cellular immunity and the serological status, *Journal of Infection*, (2023)
doi:<https://doi.org/10.1016/j.jinf.2023.05.014>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infection

Running title: Cellular immunity and the serological status

Julien Favresse^{1,2}, Julien Cabo¹, Jonathan Douxflis^{1,3}

¹*Department of Pharmacy, Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.*

²*Department of Laboratory Medicine, Clinique Saint-Luc Bouge, Namur, Belgium.*

³*Qualiblood s.a., Research and Development Department, Namur, Belgium.*

***Correspondence:**

Julien Favresse

Department of Pharmacy,

University of Namur

B-5000 Namur, Belgium

Phone +32 81 72 43 91

Email: julien.favresse@slbo.be

Keywords:

SARS-CoV-2, humoral response, cellular response, binding antibodies, interferon gamma.

Competing Interests:

The authors declare that there are no competing interests related to the present work.

Dear Editor,

Despite a substantial reduction in humoral immunity, COVID-19 vaccines still show robust protection against severe COVID-19 disease, even against highly mutated variants (1, 2). Accumulating evidence suggests that T cell response plays a key role in the protection against severe disease (i.e., hospitalization and death) (1, 3, 4). Two recent papers published in Journal of Infection (5, 6) found that the cellular immunity as assessed with an interferon gamma (IFN γ) release assay (IGRA) declined progressively 6 to 12 months after full vaccination with various COVID-19 vaccines, especially in those with no history of SARS-

CoV-2 infection. In the present study, we would like to confirm these findings and to show the impact of the second booster administration on the cellular immunity; a feature not explored in the two above-mentioned studies.

On September 2022, 54 participants of the CRO-VAX-HCP study (7) received the second and bivalent adapted BNT162b2 booster. Forty were females (median age = 51.0 years; IQR = 43.3–58.8) and 14 were males (median age = 52.5 years; IQR = 43.8–59.8). Age was not different between females and males ($p = 0.60$, Man-Whitney test). Most of the participants (45/54; 83.3%) had a history of SARS-CoV-2 infection. Blood was collected in lithium heparin and serum separator tubes (BD Vacutainer, Becton Dickinson, New Jersey, USA) just before and 28 days after the booster administration. The study was approved by a central ethical committee (CHU UCL Namur, Yvoir, Belgium; approval number: 2020-006149-21). Total antibodies against the NCP (Roche Diagnostics) were measured using the Elecsys Anti-SARS-CoV-2 assay. Results above 1.0 cut-off index (COI) were considered positive and indicates a previous SARS-CoV-2 infection. Moreover, the T cell-mediated immune response was assessed using the cobas IGRA SARS-COV-2 Tubes and the Elecsys IGRA SARS-CoV-2 assay (Roche Diagnostics). The test measures the release of interferon gamma (IFN γ) from T cells in response to an *in vitro* SARS-CoV-2 stimulation in whole blood samples which have been formerly in contact with SARS-CoV-2 coated antigens (8). Median and interquartile range (IQR) were used to present the data. A Mann-Whitney test was used to assess the impact of the second booster on cellular immunity. A multiple comparison test was used to evaluate the effect of anti-NCP levels on the cellular immunity. Results were categorized as < 1.0 COI, 1.0 to 10.0 COI and >10.0 COI. A Spearman correlation was also performed for the comparison between anti-NCP and IFN γ . Statistical analyses were performed using GraphPad Prism 9.5.1 (GraphPad Software, Massachusetts, USA). $p < 0.05$ was considered statistically significant.

Before the second booster administration, we found a significant and positive correlation between anti-NCP and IFN γ ($r = 0.39$ (95%CI = 0.11–0.61), $p = 0.005$). Individuals with negative anti-NCP had significantly lower levels of IFN γ as compared to individuals with high anti-NCP, i.e. >10.0 COI (IFN γ level of 0.18 versus 1.00 IU/mL, $p = 0.007$). These data are consistent with those published by Bonnet *et al.* and Pighi *et al.* (5, 6). One month after the bivalent booster administration, a significant increase in IFN γ was only observed for individuals with no history of SARS-CoV-2 infection (from 0.18 to 0.51 IU/mL, fold-increase = 2.85, $p = 0.04$). Mean fold increase 28 days after the bivalent booster in individuals with positive anti-NCP were close to 1 (i.e., 1.09 and 1.02) (**Table 1 and Figure 1**). Additionally, the correlation between anti-NCP and IFN γ was no longer significant after the second booster administration ($r = 0.14$ (-0.14-0.40), $p = 0.30$).


Based on these findings, we confirm that individuals with no history of SARS-CoV-2 infection presented a reduced cellular immunity but were those that were more susceptible to benefit from a second booster in terms of cellular immunity. These findings need to be confirmed in other studies with a larger population.

Table 1: INF γ levels before and after the bivalent booster in subjects with low (< 1.0 COI), intermediate (1-10 COI) and high (> 10 COI) anti-NCP antibodies.

Anti-NCP (COI)	Before booster	After booster	Fold-increase	P value
<1 (n = 9)	0.18 IU/mL 95%CI: 0.08–0.90	0.51 IU/mL 95%CI: 0.33–1.87	2.85	0.04 (*)
1–10 (n = 21)	0.63 IU/mL 95%CI: 0.36–0.73	0.69 IU/mL 95%CI: 0.40–1.6	1.09	0.22 (ns)
>10 (n = 24)	1.00 IU/mL 95%CI: 0.48–2.30	1.02 IU/mL 95%CI: 0.60–1.93	1.02	0.97 (ns)

Figure 1: Comparison of INF γ levels before and after the bivalent booster in subjects with low (< 1.0 COI), intermediate (1-10 COI) and high (> 10 COI) anti-NCP antibodies.

Results were only statistically different before booster administration between subjects with low and high anti-NCP antibodies.



References:

1. Wherry EJ, Barouch DH. T cell immunity to COVID-19 vaccines. *Science*. 2022 Aug 19;377(6608):821-2. PubMed PMID: 35981045. Epub 20220818.
2. Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol*. 2022 Feb;23(2):186-93. PubMed PMID: 35105982. Epub 2022/02/03.
3. Ledford H. 'Killer' immune cells still recognize Omicron variant. *Nature*. 2022 Jan;601(7893):307. PubMed PMID: 35017690. Epub 2022/01/13.
4. Lippi G, Mattiuzzi C, Henry BM. Is cellular immunity the future key for deciphering and monitoring COVID-19 vaccines efficacy? *Journal of Laboratory and Precision Medicine*. 2022;7.
5. Pighi L, Henry BM, De Nitto S, Salvagno GL, Lippi G. Cellular immunity against SARS-CoV-2 depends on the serological status. *J Infect*. 2023 Apr 14. PubMed PMID: 37060925. Pubmed Central PMCID: PMC10102536. Epub 20230414.
6. Bonnet B, Chabrolles H, Archimbaud C, Brebion A, Godignon M, Dutheil F, et al. Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination. *Journal of Infection*. 2022 2022-05-01;84(5):e45-e7.
7. Favresse J, Gillot C, Bayart JL, David C, Simon G, Wauthier L, et al. Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. *J Med Virol*. 2023 Jan;95(1):e28164. PubMed PMID: 36131356. Pubmed Central PMCID: PMC9538323. Epub 2022/09/22.
8. Salvagno GL, Pighi L, Henry BM, Valentini M, Tonin B, Bragantini D, et al. Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity. *Clin Chem Lab Med*. 2023 Feb 2. PubMed PMID: 36722026. Epub 2023/02/02.

Acknowledgments

None.

Research funding

None declared.

Author contributions

All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests

Authors state no conflict of interest.

Informed consent

All subjects recruited provided written informed consents for participation.

Ethical approval

The study was approved by a central ethical committee (CHU UCL Namur, Yvoir, Belgium; approval number: 2020-006149-21).

Declaration of Competing Interest

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Authors state no conflict of interest.

Journal Pre-proof